These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21569010)

  • 21. Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Ng HL; Robinson ME; May PC; Innes AJ; Hiemeyer C; Feldhahn N
    Br J Haematol; 2024 Mar; 204(3):945-958. PubMed ID: 38296260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in MECOM, Encoding Oncoprotein EVI1, Cause Radioulnar Synostosis with Amegakaryocytic Thrombocytopenia.
    Niihori T; Ouchi-Uchiyama M; Sasahara Y; Kaneko T; Hashii Y; Irie M; Sato A; Saito-Nanjo Y; Funayama R; Nagashima T; Inoue S; Nakayama K; Ozono K; Kure S; Matsubara Y; Imaizumi M; Aoki Y
    Am J Hum Genet; 2015 Dec; 97(6):848-54. PubMed ID: 26581901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
    Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
    Watanabe-Okochi N; Yoshimi A; Sato T; Ikeda T; Kumano K; Taoka K; Satoh Y; Shinohara A; Tsuruta T; Masuda A; Yokota H; Yatomi Y; Takahashi K; Kitaura J; Kitamura T; Kurokawa M
    Blood; 2013 May; 121(20):4142-55. PubMed ID: 23547050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III.
    Roy P; Reavey E; Rayne M; Roy S; Abed El Baky M; Ishii Y; Bartholomew C
    FEBS J; 2010 Jan; 277(2):441-52. PubMed ID: 20015077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
    Tokita K; Maki K; Mitani K
    Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD.
    Spensberger D; Vermeulen M; Le Guezennec X; Beekman R; van Hoven A; Bindels E; Stunnenberg H; Delwel R
    Biochemistry; 2008 Jun; 47(24):6418-26. PubMed ID: 18500823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EVI1 splice variants modulate functional responses in ovarian cancer cells.
    Dutta P; Bui T; Bauckman KA; Keyomarsi K; Mills GB; Nanjundan M
    Mol Oncol; 2013 Jun; 7(3):647-68. PubMed ID: 23517670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
    Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
    PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The EVI1 gene in myeloid leukemia.
    Nucifora G
    Leukemia; 1997 Dec; 11(12):2022-31. PubMed ID: 9447815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
    Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
    Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.
    Lavallée VP; Gendron P; Lemieux S; D'Angelo G; Hébert J; Sauvageau G
    Blood; 2015 Jan; 125(1):140-3. PubMed ID: 25331116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of EVI1 in normal and leukemic cells.
    Buonamici S; Chakraborty S; Senyuk V; Nucifora G
    Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
    Ho PA; Alonzo TA; Gerbing RB; Pollard JA; Hirsch B; Raimondi SC; Cooper T; Gamis AS; Meshinchi S
    Br J Haematol; 2013 Sep; 162(5):670-7. PubMed ID: 23826732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
    Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
    Russell M; List A; Greenberg P; Woodward S; Glinsmann B; Parganas E; Ihle J; Taetle R
    Blood; 1994 Aug; 84(4):1243-8. PubMed ID: 8049440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogene
    Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
    Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
    Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
    PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
    Shimada K; Tomita A; Minami Y; Abe A; Hind CK; Kiyoi H; Cragg MS; Naoe T
    Exp Hematol; 2012 Sep; 40(9):724-737.e2. PubMed ID: 22634393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.
    Bard-Chapeau EA; Szumska D; Jacob B; Chua BQ; Chatterjee GC; Zhang Y; Ward JM; Urun F; Kinameri E; Vincent SD; Ahmed S; Bhattacharya S; Osato M; Perkins AS; Moore AW; Jenkins NA; Copeland NG
    PLoS One; 2014; 9(2):e89397. PubMed ID: 24586749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.